These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Prognosis
1194 results:

  • 1. [Research Progress on Prognostic Factors in Patients with Lower-Risk Myelodysplastic Syndrome--Review].
    Liu JN; Chen BA; Cheng J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Oct; 32(5):1626-1630. PubMed ID: 39479859
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RNA methylation sequencing shows different gene expression signatures for response to azacytidine therapy in high-grade myelodysplastic syndromes.
    Gulei D; Moisoiu V; Kegyes D; Drula R; Iluta S; Tigu AB; Nistor M; Jitaru C; Bancos A; Rotariu P; Popovici C; Dima D; Tomai R; Rus I; Constantinescu C; Munteanu R; Cenariu D; Sezerman U; Zdrenghea M; Cermak J; Einsele H; Ghiaur G; Tomuleasa C
    J Cell Mol Med; 2024 Sep; 28(18):e70078. PubMed ID: 39334509
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study].
    Liu XZ; Zhou SJ; Huang J; Zhao CF; Jiang LX; Zhang YD; Mei C; Ma LY; Zhou XP; Shao YP; Wu GQ; Xiao XB; Yao RX; Du XH; Hu TL; Qian SX; Li Y; Yan XF; Huang L; Wang ML; Fu JP; Shou LH; Jiang WH; Jin WM; Li LJ; Le J; Luo WJ; Zhang Y; Zhou XJ; Zhang H; Lang XH; Zhou M; Jin J; Jiang HF; Zhang J; Ouyang GF; Tong HY
    Zhonghua Xue Ye Xue Za Zhi; 2024 Aug; 45(8):738-747. PubMed ID: 39307720
    [No Abstract]    [Full Text] [Related]  

  • 4. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.
    DiNardo CD; Verma D; Baran N; Bhagat TD; Skwarska A; Lodi A; Saxena K; Cai T; Su X; Guerra VA; Poigaialwar G; Kuruvilla VM; Konoplev S; Gordon-Mitchell S; Pradhan K; Aluri S; Hackman GL; Chaudhry S; Collins M; Sweeney SR; Busquets J; Rathore AS; Deng Q; Green MR; Grant S; Demo S; Choudhary GS; Sahu S; Agarwal B; Spodek M; Thiruthuvanathan V; Will B; Steidl U; Tippett GD; Burger J; Borthakur G; Jabbour E; Pemmaraju N; Kadia T; Kornblau S; Daver NG; Naqvi K; Short NJ; Garcia-Manero G; Tiziani S; Verma A; Konopleva M
    Nat Cancer; 2024 Oct; 5(10):1515-1533. PubMed ID: 39300320
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
    Wang M; Chen P; Li D; Zhao M
    Mol Biol Rep; 2024 Sep; 51(1):985. PubMed ID: 39278886
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Nakamura M; Chonabayashi K; Narita M; Matsumura Y; Nishikawa M; Ochi Y; Nannya Y; Hishizawa M; Inoue D; Delwel R; Ogawa S; Takaori-Kondo A; Yoshida Y
    Br J Haematol; 2024 Oct; 205(4):1430-1443. PubMed ID: 39187468
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Variation characteristics and clinical significance of
    Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R
    Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716
    [No Abstract]    [Full Text] [Related]  

  • 8. Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.
    Wu Q; Zhang Y; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Cheng J; Long Z; Jiang X
    Cancer Med; 2024 Aug; 13(15):e70102. PubMed ID: 39126219
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
    Smith E; Atenafu EG; Bankar A; Chan S; Davidson M; Gupta V; Minden MD; Richard-Carpentier G; Schimmer A; Schuh AC; Sibai H; Yee K; Maze D
    Eur J Haematol; 2024 Nov; 113(5):716-726. PubMed ID: 39113600
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Clinical features and prognosis of patients with myeloid neoplasms harboring t(7;11)(p15;p15) translocation: a single-center retrospective study.
    Liu L; Zhao S; Wang L; Xu H; Chen Z; Tu J; Huang J; Jin J; Tong H
    BMC Cancer; 2024 Aug; 24(1):955. PubMed ID: 39103751
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Current challenges in conditioning regimens for mds transplantation.
    Notarantonio AB; Robin M; D'Aveni M
    Blood Rev; 2024 Sep; 67():101223. PubMed ID: 39089962
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. TRANSFORMATION OF MYELODYSPLASTIC SYNDROME INTO ACUTE MYELOBLASTIC leukemia (CLINICAL CASE).
    Baidurin S; Bekenova F; Baitenova L; Darybaeva A; Kurmangalieva K
    Georgian Med News; 2024 May; (350):98-102. PubMed ID: 39089279
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion.
    Montoro MJ; Palomo L; Haferlach C; Acha P; Chan O; Navarro V; Kubota Y; Schulz FI; Meggendorfer M; Briski R; Al Ali N; Xicoy B; López-Cadenas F; Bosch F; González T; Eder LN; Jerez A; Wang YH; Campagna A; Santini V; Bernal Del Castillo T; Such E; Tien HF; Diaz Varela N; Platzbecker U; Haase D; Díez-Campelo M; Della Porta M; Garcia-Manero G; Wiseman DH; Germing U; Maciejewski JP; Komrokji RS; Sole F; Haferlach T; Valcárcel D
    Blood; 2024 Oct; 144(16):1722-1731. PubMed ID: 39074355
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.
    Márton A; Veres KB; Erdődi F; Udvardy M; Illés Á; Rejtő L
    Pathol Oncol Res; 2024; 30():1611747. PubMed ID: 39035053
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Computing cell state discriminates the aberrant hematopoiesis and activated microenvironment in Myelodysplastic syndrome (mds) through a single cell genomic study.
    Guo X; Jin W; Wen Y; Wang Z; Ren X; Liu Z; Fu R; Cai Z; Li L
    J Transl Med; 2024 Jul; 22(1):673. PubMed ID: 39033303
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
    Jann JC; Hergott CB; Winkler M; Liu Y; Braun B; Charles A; Copson KM; Barua S; Meggendorfer M; Nadarajah N; Shimony S; Winer ES; Wadleigh M; Stone RM; DeAngelo DJ; Garcia JS; Haferlach T; Lindsley RC; Luskin MR; Stahl M; Tothova Z
    Leukemia; 2024 Sep; 38(9):1992-2002. PubMed ID: 39033241
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia].
    Chen SL; Shi YY; Zhang LN; Gong M; Zhang XY; Zhao XL; Hao MZ; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):364-369. PubMed ID: 38951064
    [No Abstract]    [Full Text] [Related]  

  • 18. Fetal hemoglobin induction in azacytidine responders enlightens methylation patterns related to blast clearance in higher-risk mds and CMML.
    Chatzilygeroudi T; Chondrou V; Boers R; Siamoglou S; Athanasopoulou K; Verigou E; Gribnau J; Alexis S; Labropoulou V; Kourakli A; Patrinos GP; Sgourou A; Symeonidis A
    Clin Epigenetics; 2024 Jun; 16(1):79. PubMed ID: 38879530
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. High hyperdiploid karyotype with ≥ 49 chromosomes represents a heterogeneous subgroup of acute myeloid leukemia with differential TP53 mutation status and prognosis: a single-center study from China.
    Zhang Z; Fu C; Sun Y; Liu Y; Wang Q; Yan W; Wu C; Wang Q; Zeng Z; Wen L; Shen H; Yao L; Liu D; Chen S; Pan J
    Ann Hematol; 2024 Jul; 103(7):2337-2346. PubMed ID: 38849603
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 60.